Trial Profile
A Multi-Center, Randomized, Controlled Study to Investigate the Safety and Tolerability of Intravenous Ferric Carboxymaltose (FCM) vs. Iron Dextran in Treating Iron Deficiency Anemia
Status:
Completed
Phase of Trial:
Phase III
Latest Information Update: 06 Nov 2021
Price :
$35
*
At a glance
- Drugs Ferric carboxymaltose (Primary) ; Iron dextran
- Indications Iron deficiency anaemia
- Focus Adverse reactions
- Sponsors American Regent; Luitpold Pharmaceuticals
- 26 Jun 2014 New trial record